Ipsen acquires botulinum therapeutic developer
This article was originally published in Scrip
Ipsen of France has acquired Syntaxin, a privately-held UK biotech developing botulinum toxin therapeutics, for €28m upfront and potential contingent payments to its shareholders of more than €130m dependent on development and commercial milestones. Ipsen already holds around 10% of Syntaxin.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.